Educational analysis only — not financial advice. Always do your own due diligence.
Merck is a mature cash-generator currently heavily reliant on its blockbuster oncology drug Keytruda and the Gardasil vaccine franchise. While near-term cash flows and dividend safety are robust, the long-term investment thesis hinges on management's ability to successfully commercialize its pipeline of Antibody-Drug Conjugates (ADCs) and leverage M&A to offset the massive patent cliff approaching in 2028.
A severe stress test assumes structural earnings decline post-2028 as Keytruda revenues drop, combined with a failure to realize ADC revenue and M&A integration issues, compressing gross margins.
Failure to offset Keytruda LOE through M&A or internal ADC pipeline leaves a massive revenue gap, severely compressing structural margins.
Late-stage clinical failures in the Antibody-Drug Conjugate pipeline erode future growth vectors, stalling the dividend trajectory.
Aggressive regulatory pricing pressures from the IRA compress margins more sharply than modeled, stunting near-term operating cash flows.
Cash-flow quality is reflected in the OCFOperating cash flowCash generated from the company's core operations after working-capital changes but before capital expenditures. The first line of the cash-flow statement. / net income, accounting-quality, and ROICROICReturn on invested capital. Operating profit (after tax) divided by invested capital. The single best gauge of capital-efficiency. Spread over WACC = economic value created. rows above.
Capital allocation should be evaluated against reinvestment needs, balance-sheet strength, and shareholder returns.
